More Positive Data For Recordati Cushing's Drug
Isturisa Could Become A Big Earner
Executive Summary
With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.
You may also be interested in...
More Competition Coming To Cushing's Market
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space
Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
Strongbridge Makes Case For Recorlev In First-Line Cushing's Disease
Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.